eligibility_summary
Eligible: MM per IMWG with 1–4 prior lines including anti‑CD38 and lenalidomide, progressing/refractory, measurable disease (M‑protein or FLC), adequate labs, ECOG ≤2, not pregnant/breastfeeding and using contraception. Exclude: smoldering MM, plasma cell leukemia, amyloidosis, POEMS, CNS disease, SCT <12 wks or GVHD, active infection, recent other malignancy, prior BCMA/CD3 therapy, unable to get investigator’s choice, recent live vaccine or investigational drug.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 trial in relapsed/refractory multiple myeloma compares: 1) Elranatamab: a subcutaneous bispecific T‑cell–engaging antibody (BCMA×CD3). Mechanism: binds BCMA on malignant plasma cells and CD3 on T cells to redirect cytotoxic T cells and induce myeloma cell lysis. Targets: BCMA+ plasma cells, T‑cell activation via CD3. 2) Investigator’s choice regimens: • Elotuzumab (IV anti‑SLAMF7 monoclonal antibody) + pomalidomide + dexamethasone: enhances NK‑cell–mediated ADCC and immune activation. Targets: SLAMF7 on myeloma and NK cells, NK cell pathway. • Pomalidomide (oral IMiD/CRBN E3 ligase modulator) degrades IKZF1/3, augments T/NK activation, anti‑angiogenic. Targets: cereblon–IKZF pathway. • Bortezomib (reversible proteasome inhibitor) and • Carfilzomib (irreversible proteasome inhibitor): inhibit 26S proteasome, suppress NF‑κB, induce ER stress/apoptosis. • Dexamethasone: glucocorticoid inducing lymphoid apoptosis.